The primary goal of pancreatic cancer surgery is total microscopic removal of the tumor with clear surgical margins, known as an R0 resection. Surgical oncology guidelines established by the National Comprehensive Cancer Network (NCCN 2024) classify tumors as resectable, borderline resectable, or locally advanced based on vascular involvement. Surgery targets localized disease to prevent systemic spreading and relieve biliary or intestinal blockages caused by tumor mass effect.

The surgeon makes an incision in the upper abdomen or uses minimally invasive laparoscopic or robotic techniques. The head of the pancreas, the first portion of the small intestine (duodenum), the gallbladder, and the lower portion of the common bile duct are carefully detached and removed. If performing a classic Whipple, part of the stomach is removed; if performing a pylorus-preserving procedure, the stomach valve is preserved. Reconstruction requires three connections (anastomoses): connecting the remaining pancreas to the small intestine (pancreaticojejunostomy), connecting the remaining bile duct to the small intestine (hepatojejunostomy), and connecting the stomach to the small intestine (gastrojejunostomy). Surgical drains are placed before closure.

Surgical resection offers the only potential long-term cure for pancreatic ductal adenocarcinoma. Evidence from the American Society of Clinical Oncology (ASCO 2023) demonstrates that complete surgical removal combined with modern adjuvant chemotherapy significantly improves overall survival compared to non-surgical therapies alone. Additional benefits include relief of biliary obstruction, prevention of duodenal blockade, and accurate pathological staging to direct targeted postoperative treatments.

In-hospital recovery takes 7 to 14 days, during which oral intake is slowly reintroduced as gastrointestinal function returns. Full physical recovery takes 2 to 3 months. Patients typically resume daily activities within 6 to 8 weeks. Long-term dietary modifications are common, and many individuals require supplemental pancreatic enzymes to aid fat digestion and insulin to manage blood glucose levels.

Pancreatic cancer surgery is indicated for malignant and premalignant conditions of the pancreas and periampullary region. Primary indications include pancreatic ductal adenocarcinoma located in the head or uncinate process, ampullary carcinoma, distal cholangiocarcinoma, and duodenal adenocarcinoma. It is also utilized for high-risk intraductal papillary mucinous neoplasms (IPMN), pancreatic neuroendocrine tumors (pNETs), and severe localized chronic pancreatitis.

Preparation involves contrast-enhanced pancreas-protocol CT scanning and magnetic resonance cholangiopancreatography (MRCP) for anatomical staging. Positron emission tomography (PET) may rule out distant disease. Endoscopic ultrasound (EUS) with fine-needle aspiration provides tissue confirmation. Patients undergo cardiopulmonary evaluation, nutritional assessment, and prehabilitation exercises. Complete bowel preparation is generally not required, but fasting begins the night before surgery. Blood thinners are paused under clinical guidance.

Complications include postoperative pancreatic fistula (POPF), where pancreatic fluid leaks from the surgical connection; delayed gastric emptying (DGE), causing temporary stomach paralysis; post-pancreatectomy hemorrhage; intra-abdominal abscesses or fluid collections; wound infection; new-onset diabetes mellitus; pancreatic exocrine insufficiency causing malabsorption; and general risks of deep vein thrombosis, pneumonia, or cardiac events.

The surgical journey spans four distinct phases. The pre-treatment phase involves multi-phase imaging, endoscopic staging, and medical prehabilitation. The procedure phase lasts 4 to 8 hours under general anesthesia in a specialized hospital setting. The immediate recovery phase requires 7 to 14 days in the hospital to monitor organ function and manage surgical drains. The long-term phase involves rehabilitation, nutritional adjustments with pancreatic enzyme replacement therapy (PERT), and adjuvant systemic chemotherapy.